Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2011 - 2026)
Supernus Pharmaceuticals' (SUPN) quarterly Interest & Investment Income came in at -$211000.0 in Q1 2026, down 803.33% year-on-year from $30000.0 in Q1 2025, and down 414.63% on a QoQ basis from -$41000.0 in Q2 2025.
Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 14 years of Interest & Investment Income data on file, last reported at -$211000.0 in Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 803.33% year-over-year to -$211000.0 in Q1 2026; TTM through Mar 2026 was -$60000.0, a 107.45% decrease from a year earlier, with the FY2018 full-year figure at $13.8 million, up 383.34% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$211000.0, down from -$41000.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for SUPN reached as high as $881000.0 in Q1 2023 and fell as low as -$211000.0 in Q1 2026.
- Historically, Interest & Investment Income has averaged $204857.1 across 4 years, with a median of $59000.0 in 2024.
- Across the five-year window, Interest & Investment Income plunged 49.15% in 2025 and slumped 803.33% in 2026, its largest moves.
- Year by year, Interest & Investment Income stood at $554000.0 in 2023, then plunged by 70.76% to $162000.0 in 2024, then sank by 125.31% to -$41000.0 in 2025, then tumbled by 414.63% to -$211000.0 in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were -$211000.0 in Q1 2026, -$41000.0 in Q2 2025, and $30000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - | -211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -211,000.00 |
| Jun 30, 2025 | -41,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Jun 30, 2023 | 554,000.00 |
| Mar 31, 2023 | 881,000.00 |
| Sep 30, 2020 | 3.26 Mn |
| Sep 30, 2019 | 5.56 Mn |
| Jun 30, 2019 | 5.45 Mn |
| Mar 31, 2019 | 4.68 Mn |
| Dec 31, 2018 | 4.51 Mn |
| Sep 30, 2018 | 4.46 Mn |
| Jun 30, 2018 | 3.66 Mn |
| Mar 31, 2018 | 1.21 Mn |
| Dec 31, 2017 | 862,000.00 |
| Sep 30, 2017 | 814,000.00 |
| Jun 30, 2017 | 656,000.00 |
| Mar 31, 2017 | 531,000.00 |
| Dec 31, 2016 | 396,000.00 |